Cardiovascular diseases are one of the leading causes of death whereas hypertension remains a significant cause of cardiovascular morbidity and mortality. Failure of effective treatment forms a tremendous scope for the formulator to develop the new anti-hypertensive entity, dosage form or fixed dose combinations such as a newly approved combination of angiotensin receptor blocker and thiazide diuretic. With increase in development of fixed dose combinations there should be simultaneous increase in development of validated method for detection. In the present work RP-HPLC dissolution method was developed for simultaneous detection of azilsartan medoxomil potassium and chlorthalidone from the formulated tablet. The method was carried out using Zorbax XDB column (C8, 150 X 4.6 mm, 5 µ). The mobile phase was Buffer (pH 7.8): acetonitrile (650:350) and 2 ml of triethylamine with flow rate 1.0 ml/min at 240 nm detector wavelength. The retention time for azilsartan medoxomil potassium was found to be 2.6 min. and for chlorthalidone it was found to be 8.7 minutes. The developed method was found to be stable, simple and robust.
Loading....